- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: Anti PD-1
Total 185456 results
-
NYU Langone HealthMerck Sharp & Dohme LLCTerminatedSmall Cell Lung Cancer (SCLC)United States
-
Merck Sharp & Dohme LLCActive, not recruitingSmall Cell Lung CancerPoland, Russian Federation, United States, Austria, Canada, Hungary, Israel, Italy, Korea, Republic of, Spain, Switzerland
-
Merck Sharp & Dohme LLCEisai Inc.Active, not recruitingRenal Cell CarcinomaPoland, Australia, United States, Canada, France, Hungary, Ireland, Italy, Korea, Republic of, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
-
Mahmoud Ramadan mohamed ElkazzazNot yet recruiting
-
RenJi HospitalRecruitingUrothelial Carcinoma Bladder | PD-1 InhibitorChina
-
Chinese PLA General HospitalLinkDoc Technology (Beijing) Co. Ltd.UnknownAdvanced Solid TumorsChina
-
Tianjin Medical University Cancer Institute and...Jiangsu HengRui Medicine Co., Ltd.Completed
-
Boehringer IngelheimActive, not recruitingHeart FailureCzechia, Switzerland, Poland, Hungary, Romania, Bulgaria
-
Diwakar DavarMerck Sharp & Dohme LLCActive, not recruitingSquamous Cell CarcinomaUnited States
-
The Affiliated Hospital of Qingdao UniversityUnknown
-
RenJi HospitalBeiGene; Huidu Shanghai Medical Sciences LtdRecruitingUrologic Neoplasms | Urogenital Neoplasms | Urinary Bladder Diseases | Urinary Bladder Neoplasms | Antineoplastic Agents | Tislelizumab Antineoplastic Agents, ImmunologicalChina
-
Merck Sharp & Dohme LLCRecruitingLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Hodgkin DiseaseUnited States, Australia, Canada, Germany, Israel, Italy
-
Merck Sharp & Dohme LLCEisai Inc.CompletedNon-small Cell Lung CancerChina
-
Merck Sharp & Dohme LLCEisai Inc.Active, not recruitingMetastatic Non-Small Cell Lung CancerRussian Federation, Australia, United States, Argentina, Canada, Colombia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Puerto Rico, Spain, United Kingdom
-
Merck Sharp & Dohme LLCEisai Inc.Active, not recruitingNonsquamous Non-small Cell Lung CancerChina
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Hunan Cancer HospitalCompleted
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruiting
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
Xuanwu Hospital, BeijingUnknownNon-small Cell Lung Cancer | PD-1 Antibody | Lung Cancer Stage II
-
The First Affiliated Hospital with Nanjing Medical...Jiangsu HengRui Medicine Co., Ltd.CompletedCholangiocarcinoma | Biliary Tract CancerChina
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
HotSpot Therapeutics, IncRecruitingSolid Tumor, Adult | Relapsed Cancer | Refractory CancerUnited States
-
Second Affiliated Hospital, School of Medicine,...RecruitingCarotid Artery Plaque | Pd-1 InhibitorsChina
-
Merck Sharp & Dohme LLCActive, not recruitingStomach NeoplasmsChina, Japan, Poland, Turkey, Brazil, United States, Argentina, Australia, Canada, Chile, Colombia, Costa Rica, Czechia, Denmark, France, Germany, Guatemala, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Republic of, Mexico, New Zealand and more
-
Merck Sharp & Dohme LLCEisai Inc.Active, not recruitingMalignant MelanomaUnited States, Australia, Austria, Brazil, Canada, Chile, China, France, Germany, Israel, Italy, Korea, Republic of, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
-
Merck Sharp & Dohme LLCEisai Inc.Active, not recruiting
-
Merck Sharp & Dohme LLCWithdrawn
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
-
Second Affiliated Hospital of Soochow UniversitySciClone PharmaceuticalsRecruitingAdvanced Solid Tumor | Refractory TumorChina
-
Shanghai Junshi Bioscience Co., Ltd.Completed
-
Peking UniversityNot yet recruiting
-
Merck Sharp & Dohme LLCCompleted
-
Hoffmann-La RocheCompletedBladder CancerUnited States, Spain, United Kingdom, Canada, France, Germany, Italy, Netherlands
-
Fudan UniversityRecruitingCarcinosarcoma | Sarcomatoid Carcinoma | PD-1 Immunotherapy | VEGFR-TKIChina
-
Sun Yat-sen UniversityRecruitingImmunotherapy | DMMR Colorectal Cancer | Anti PD-1China
-
Shanghai Zhongshan HospitalJining Medical University; Cancer Hospital of Guangxi Medical UniversityActive, not recruitingBiliary Tract CarcinomaChina
-
Chinese PLA General HospitalRecruitingHodgkin Lymphoma | Anti-PD-1 Antibody ResistantChina
-
Merck Sharp & Dohme LLCCompletedMelanomaAustralia, South Africa, Spain, Sweden
-
Fudan UniversityRecruiting
-
Changhai HospitalNot yet recruitingHER-2 Protein Overexpression | Esophageal Squamous Carcinoma
-
Coherus Biosciences, Inc.Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.Active, not recruitingHepatocellular Carcinoma | Non-Small Cell Lung Cancer | Advanced Solid TumorUnited States
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
Agenus Inc.Withdrawn
-
Second Military Medical UniversityUnknownAdvanced Hepatocellular CarcinomaChina
-
Merck Sharp & Dohme LLCCompleted
-
Hoffmann-La RocheCompletedBladder CancerUnited States, Spain, United Kingdom, Canada, France, Germany, Italy, Netherlands
-
University Medical Center GroningenActive, not recruitingLocally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 ExpressionNetherlands